Arkolith/Insider Trading/HALO/Form 4

Torley Helen

PRESIDENT AND CEO, DirectorHALOZYME THERAPEUTICS, INC. (HALO) · full profile →Form 4 · filed Feb 24, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 23, 2026Option exercise(M)22K—$0780K
Feb 23, 2026Tax withholding(F)12K$70.64$855K768K
Feb 20, 2026Option exercise(M)17K—$0766K
Feb 20, 2026Tax withholding(F)9K$70.98$642K757K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 23, 2026Option exercise(M)22K—$045K
Feb 20, 2026Option exercise(M)17K—$050K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001159036-26-000028) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML